Literature DB >> 27179211

Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction.

Antonella De Angelis1, Donato Cappetta1, Elena Piegari1, Barbara Rinaldi1, Loreta Pia Ciuffreda1, Grazia Esposito1, Fiorella Angelica Valeria Ferraiolo1, Alessia Rivellino1, Rosa Russo1, Maria Donniacuo1, Francesco Rossi1, Konrad Urbanek2, Liberato Berrino1.   

Abstract

BACKGROUND: To investigate the effects of chronic administration of ranolazine (RAN) on experimental model of heart failure with preserved ejection fraction.
METHODS: Seven-weeks old Dahl salt-sensitive rats were fed a high salt diet for 5weeks to induce hypertension. Afterwards, rats continued with a high salt diet and were administered either with vehicle or RAN (20mg/kg/die, ip) for the following 8weeks. Control rats were maintained on a low salt diet.
RESULTS: While systolic parameters were not altered, diastolic parameters were changed in high salt animals. Hemodynamic analysis showed a decreased dP/dt min, increased LVEDP, longer time constant and steeper slope of the end-diastolic pressure-volume relationship. Treatment with RAN attenuated these alterations and determined a reduction in mortality. Additionally, the magnitude of myocardial hypertrophy and activation of PI3K/Akt pathway were reduced. Alteration in diastolic compliance as a consequence of elevated myocardial stiffness was confirmed by an increase of collagen deposition and activation of pro-fibrotic TGF-β/SMAD3/CTGF signaling. These effects were counteracted by RAN. High salt rats had a decrease in SERCA2 and an increase in Na(+)/Ca(2+) exchanger (NCX). Treatment with RAN reduced NCX expression and determined an increment of SERCA2. Moreover, the levels of nitrotyrosine and oxidized dyhydroethidium were higher in high salt rats. RAN induced a decrement of oxidative stress, supporting the concept that reduction in ROS may mediate beneficial effects.
CONCLUSIONS: Our findings support the possibility that diastolic dysfunction can be attenuated by RAN, indicating its ability to affect active relaxation and passive diastolic compliance.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dahl salt-sensitive rats; Diastolic dysfunction; Heart failure with preserved ejection fraction; Ranolazine

Mesh:

Substances:

Year:  2016        PMID: 27179211     DOI: 10.1016/j.ijcard.2016.04.168

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

Review 1.  Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future.

Authors:  Bibhuti B Das
Journal:  Paediatr Drugs       Date:  2022-05-02       Impact factor: 3.022

2.  Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling.

Authors:  Jiali Nie; Quanlu Duan; Mengying He; Xianqing Li; Bei Wang; Chi Zhou; Lujin Wu; Zheng Wen; Chen Chen; Dao Wu Wang; Katherina M Alsina; Xander H T Wehrens; Dao Wen Wang; Li Ni
Journal:  J Cell Physiol       Date:  2018-11-29       Impact factor: 6.384

3.  Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.

Authors:  Donato Cappetta; Grazia Esposito; Raffaele Coppini; Elena Piegari; Rosa Russo; Loreta Pia Ciuffreda; Alessia Rivellino; Lorenzo Santini; Concetta Rafaniello; Cristina Scavone; Francesco Rossi; Liberato Berrino; Konrad Urbanek; Antonella De Angelis
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

4.  Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.

Authors:  Koenraad Philippaert; Subha Kalyaanamoorthy; Mohammad Fatehi; Wentong Long; Shubham Soni; Nikole J Byrne; Amy Barr; Jyoti Singh; Jordan Wong; Taylor Palechuk; Chloe Schneider; Ahmed M Darwesh; Zaid H Maayah; John M Seubert; Khaled Barakat; Jason R B Dyck; Peter E Light
Journal:  Circulation       Date:  2021-04-09       Impact factor: 29.690

5.  Cardioprotective effects of miR-34a silencing in a rat model of doxorubicin toxicity.

Authors:  Elena Piegari; Anna Cozzolino; Loreta Pia Ciuffreda; Donato Cappetta; Antonella De Angelis; Konrad Urbanek; Francesco Rossi; Liberato Berrino
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

6.  Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.

Authors:  Grazia Esposito; Donato Cappetta; Rosa Russo; Alessia Rivellino; Loreta Pia Ciuffreda; Fiorentina Roviezzo; Elena Piegari; Liberato Berrino; Francesco Rossi; Antonella De Angelis; Konrad Urbanek
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

Review 7.  Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.

Authors:  Stefania Gorini; Antonella De Angelis; Liberato Berrino; Natalia Malara; Giuseppe Rosano; Elisabetta Ferraro
Journal:  Oxid Med Cell Longev       Date:  2018-03-18       Impact factor: 6.543

8.  MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat.

Authors:  Elena Piegari; Rosa Russo; Donato Cappetta; Grazia Esposito; Konrad Urbanek; Carmela Dell'Aversana; Lucia Altucci; Liberato Berrino; Francesco Rossi; Antonella De Angelis
Journal:  Oncotarget       Date:  2016-09-20

9.  Statins Stimulate New Myocyte Formation After Myocardial Infarction by Activating Growth and Differentiation of the Endogenous Cardiac Stem Cells.

Authors:  Eleonora Cianflone; Donato Cappetta; Teresa Mancuso; Jolanda Sabatino; Fabiola Marino; Mariangela Scalise; Michele Albanese; Alessandro Salatino; Elvira Immacolata Parrotta; Giovanni Cuda; Antonella De Angelis; Liberato Berrino; Francesco Rossi; Bernardo Nadal-Ginard; Daniele Torella; Konrad Urbanek
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

10.  Deficit of glucocorticoid-induced leucine zipper amplifies angiotensin-induced cardiomyocyte hypertrophy and diastolic dysfunction.

Authors:  Donato Cappetta; Antonella De Angelis; Sara Flamini; Anna Cozzolino; Oxana Bereshchenko; Simona Ronchetti; Eleonora Cianflone; Andrea Gagliardi; Erika Ricci; Concetta Rafaniello; Francesco Rossi; Carlo Riccardi; Liberato Berrino; Stefano Bruscoli; Konrad Urbanek
Journal:  J Cell Mol Med       Date:  2020-11-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.